Apixaban Study Halted – But It May Not Cause Much Damage To The Program
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The Phase III APPRAISE-2 trial of Bristol-Myers Squibb/Pfizer’s apixaban in acute coronary syndrome has been terminated due to increased bleeding, on the recommendation of a data safety monitoring committee.
You may also be interested in...
Xarelto Back On Track: J&J Answers "Complete Response" Letter And Files For Atrial Fibrillation
Simultaneously, partner Bayer submits applications in Europe, where rivaroxaban already is approved, for those indications and one more.
Xarelto Back On Track: J&J Answers "Complete Response" Letter And Files For Atrial Fibrillation
Johnson & Johnson and Bayer HealthCare may gain a market advantage if regulators grant an approval with indications for both chronic and acute use of its anticoagulant rivaroxaban, based on regulatory filings the co-development partners announced Jan. 5.
Xarelto Back On Track: J&J Answers "Complete Response" Letter And Files For Atrial Fibrillation
Johnson & Johnson and Bayer HealthCare may gain a market advantage if regulators grant an approval with indications for both chronic and acute use of its anticoagulant rivaroxaban, based on regulatory filings the co-development partners announced Jan. 5.